Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat + R-CHOP in Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL
NCT04231448Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- May 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Event Free Survival at 5 years. Started May 2020; status: completed.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04231448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231448.